



Published in final edited form as:

Curr Behav Neurosci Rep. 2016 December ; 3(4): 350–359. doi:10.1007/s40473-016-0089-y.

Physical Exercise for Treatment of Mood Disorders: A Critical Review

CM Hearing, B.A.¹, WC Chang, B.S.¹, KL Szuhany, M.A.², T Deckersbach, Ph.D.³, AA Nierenberg, M.D.³, and LG Sylvia, Ph.D.³

¹Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. Phone number: 866-996-6637; Fax: 617-726-6768

²Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA. Phone number: 617-353-9610; Fax: 617-353-9609

³Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Phone number: 866-996-6637; Fax: 617-726-6768

Corresponding Author: Louisa G. Sylvia, Ph.D., Bipolar Clinic and Research Program, 50 Staniford Street, Suite 580, Boston, MA, 02114, lsylvia2@partners.org.

Disclosures

Ms. Hearing has no competing interests to report.

Ms. Chang has no competing interests to report.

Dr. Deckersbach's research has been funded by NIH, NIMH, NARSAD, TSA, IOCDF, Tufts University, DBDAT and Otsuka Pharmaceuticals. He has received honoraria, consultation fees and/or royalties from the MGH Psychiatry Academy, BrainCells Inc., Clintara, LLC., Systems Research and Applications Corporation, Boston University, the Catalan Agency for Health Technology Assessment and Research, the National Association of Social Workers Massachusetts, the Massachusetts Medical Society, Tufts University, NIDA, NIMH, Oxford University Press, Guilford Press, and Rutledge. He has also participated in research funded by DARPA, NIH, NIMH, NIA, AHRQ, PCORI, Janssen Pharmaceuticals, The Forest Research Institute, Shire Development Inc., Medtronic, Cyberonics, Northstar, and Takeda.

Dr. Nierenberg serves as a consultant for Abbott Laboratories, Alkermes, American Psychiatric Association, Appliance Computing Inc. (Mindsight), Basilea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaisance, Genentech, GlaxoSmithKline, Healthcare Global Village, Hoffman LaRoche, Infomedic, Intra-cellular Therapies, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, NeuroRx, Naurex, Novartis, PamLabs, Parexel, Pfizer, PGx, Health, Otsuka, Ridge Diagnostics Shire, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva; He has also consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc., Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept and Takeda/Lundbeck Pharmaceuticals. He has received grants/research support from American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Intra-Cellular Therapies, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst and honoraria from Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing and Wolters Kluwer Publishing, ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova Southeastern University, NAMI, Institute of Medicine, CME Institute, ISCTM, World Congress on Brain Behavior and Emotion, Congress of the Hellenic Society for Basic and Clinical Pharmacology, and ADAA. Dr. Nierenberg has stock in Appliance Computing, Inc. (MindSite), Brain Cells, Inc., and Medavante. He holds copyrights for Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI).

Dr. Sylvia was a shareholder in Concordant Rater Systems and has served in the past year as a consultant for United Biosource Corporation, Clintara, Bracket, and Clinical Trials Network and Institute. Dr. Sylvia receives royalties from New Harbinger. She has received grant/research support from NIMH, PCORI, AFSP, and Takeda.

Abstract

Purpose of the review—The purpose of this review is to critically assess the evidence for exercise as an adjunct intervention for major depressive disorder and bipolar disorder, chronic conditions characterized by frequent comorbid conditions as well as interepisodic symptoms with poor quality of life and impaired functioning. Individuals with these mood disorders are at higher risk of cardiovascular disease and premature death in part because of increased rates of obesity, inactivity, and diabetes mellitus compared to the general population. Exercise may not only mitigate the increased risk of cardiovascular disease, but could also potentially improve the long term outcomes of mood disorders.

Recent findings—We conducted a literature review on the impact of exercise on mood disorders and associated comorbid conditions as well as possible biological mechanisms. We found that exercise impacts both the physical health parameters of mood disorders as well as mental health outcomes. Exercise also positively impacts conditions frequently comorbid with mood disorders (i.e. anxiety, pain, and insomnia). There are multiple candidate biomarkers for exercise, with brain-derived neurotrophic factor and oxidative stress as two main promising components of exercise's anti-depressant effect.

Summary—Exercise appears to be a promising adjunct treatment for mood disorders. We conclude with recommendations for future research of exercise as an adjunct intervention for mood disorders.

Keywords

Bipolar disorder; depression; mood disorders; exercise; cardiovascular disease; adjunctive intervention

Introduction

Major depressive disorder (MDD) affects approximately 16.6% of U.S. adults in their lifetimes and bipolar disorder has a lifetime prevalence of 2.1% in U.S. adults [1, 2]. Both MDD and bipolar disorder are marked by high rates of medical and psychological comorbid conditions as well as functional impairment [2–5]. At least 64.1% of patients with MDD have another comorbid psychiatric diagnosis, and primary care patients who have MDD have also reported an average of two to three concurrent chronic medical illnesses, which is approximately double those without depression [4, 5]. Similarly, in a national epidemiological study, Merikangas and colleagues found that 92.3% of bipolar individuals have a comorbid psychiatric diagnosis and 58.8% have a comorbid medical diagnosis [2]. More specifically, Forty and colleagues found that the most prevalent comorbid medical conditions of MDD and bipolar disorder are: migraines, asthma, elevated lipids, hypertension, thyroid disease and osteoarthritis [6]. Individuals with MDD and bipolar disorder also have a higher incidence of cardiovascular disease, diabetes, and metabolic syndromes, due in part to less engagement in physical activity and more sedentary behavior as well as medication side effects (e.g., weight gain) [7–15]. These risk factors lead to earlier and higher rates of mortality for individuals with MDD and bipolar disorder compared to the general population [16]. Moreover, despite major pharmacological advances in the treatment

of MDD and bipolar disorder, as many as 19–34% of depressed patients and 30–35% of patients with bipolar disorder do not achieve remission [17, 18]. Medications used to treat severe mood disorders, such as quetiapine and lithium, are often associated with weight gain [12]. Thus, alternative augmentation strategies that target mental and physical health would be desirable. Exercise represents a cost-effective and easily disseminated intervention that includes the benefits of minimal side effects and improved physical and mental health.

The data on the efficacy of exercise as an intervention for MDD and bipolar disorder have yielded effect sizes comparable to medications [19–23]. Given the high rates of partial and non-response to pharmacological treatment and the need to improve mental and physical health outcomes, exercise may be particularly helpful for serving as an adjunctive treatment option for individuals with MDD, treatment-resistant depression, and bipolar disorder. Preliminary research also reports the benefits of exercise augmentation strategies added to cognitive-behavioral therapy for anxiety disorders or treatment as usual for depression [24, 25].

While there are some promising initial findings for bipolar disorder, there is a paucity of well-controlled studies investigating the efficacy of exercise as an intervention strategy, as well as studies investigating the pathways by which exercise may exert its effects on mood [22, 26–28]. Preliminary studies indicate its acceptability, feasibility, and efficacy for depression, bipolar disorder, and anxiety [19–22, 26–28]. In summary, exercise is an established adjunct treatment of depression with promise as an effective treatment for bipolar disorder adjunctive to mood stabilizing medication because of its broad-reaching effects on mental and physical health outcomes.

In this review, we summarize findings from studies demonstrating the role of exercise in the treatment of MDD and bipolar disorder as well as comorbid conditions. We define exercise broadly in our review given the paucity of data and the lack of consistency in the field. Specifically, exercise in this review includes anaerobic (e.g., strength training) as well as aerobic exercise (e.g., walking, cycling, running, swimming) [24, 25, 29–33]. Moreover, all forms of exercise, whether anaerobic or aerobic, light or vigorous intensity, have been shown to have positive benefits, so we included both anaerobic and aerobic types of physical activity in defining exercise [24, 25, 29, 30, 32, 34]. We also discuss potential mechanisms of exercise. Finally, we propose future directions and examine clinical implications for exercise in the treatment of mood disorders.

Exercise for Major Depressive Disorder (MDD)

MDD is the leading cause of disability for individuals ages 18 to 44 in the United States and the third greatest cause of disease burden worldwide [35]. Even with adequate pharmacological and psychosocial interventions, the rate of relapse, quality of life, and functioning often remain impaired for individuals with MDD [3, 18, 36]. Thus, new, adjunctive treatments, such as exercise, to improve depression and its comorbid conditions are needed [20, 37].

Exercise has demonstrated moderate to large effect sizes for improving depressive symptoms, suggesting exercise may be an effective adjunct treatment [19–21, 38, 39]. Randomized clinical trials have also reported that exercise improves outcomes in treatment-resistant depression, depressed patients with a chronic medical illness, and women with antenatal depression [29, 40, 41]. Another trial randomized participants with MDD to group cognitive behavioral therapy plus home-based walking program or group cognitive behavioral therapy plus educational sessions. They found that the group cognitive behavioral therapy plus a walking program improved depression, anxiety, and stress more than the control group [24].

Studies have also found that physical activity reduces the symptoms of depression as effectively as cognitive-behavioral therapy (CBT), pharmacotherapy, and even bright light therapy in individuals with MDD [23, 42, 43]. For example, a recent study randomized participants to either supervised exercise in a group setting, home-based exercise, antidepressant medication (sertraline, 50–200 mg daily), or placebo for 16 weeks [23]. After 16 weeks of treatment, participants receiving active treatments tended to have higher remission rates than the placebo controls and those receiving supervised exercise had similar remission rates to that of antidepressants (i.e., supervised exercise = 45%; home-based exercise = 40%; medication = 47%; placebo = 31%). Similarly, a second study found that when compared to a sedentary control group, the patients randomized to an aerobic exercise group required a lower dosage of sertraline than did the individuals in the sertraline monotherapy treatment condition [30].

There have only been a few studies that have reported the effects of adding exercise to psychological treatments of depression. Previous reviews and meta-analyses have also raised concerns over the methodological quality of existing studies examining the effects of exercise on depression. Specifically, these reviews and meta-analyses noted overestimation of treatment effects, and lack of long term follow-up data as limitations to the existing literature [20, 38, 39]. Adherence rates for exercise-based interventions are comparable to those found in pharmacotherapy and other psychotherapeutic treatments, but still remain low. Another limitation of adjunctive exercise is that there appears to be many possible biomarkers of exercise that likely interact with one another, which makes interventions that target exercise challenging. It is also challenging to engage depressed individuals in exercise interventions, particularly those with anhedonia, given the lack of interest and motivation inherent in this condition [44, 45]. Thus, future research of adjunct exercise interventions should include randomized clinical trials with strong methodological designs and control groups, biological outcome measures, and examination of moderating variables (to identify those who may benefit most from these interventions).

Exercise for Bipolar Disorder

Bipolar individuals are more likely to lead a sedentary lifestyle [13–15]. They experience higher levels of pain when exercising, have lower exercise capacity, and engage in less overall physical activity because they perceive exercise to be aversive [46]. Low levels of exercise have been linked to poorer quality of life, worse functioning, and more depressive symptoms [28, 47]. Regular physical activity and higher levels of cardiorespiratory fitness in

individuals with bipolar disorder are associated with lower risk for premature mortality. Additionally, exercise training has also been demonstrated to improve a number of important risk factors, such as cardiorespiratory fitness, weight, and high-density lipoprotein cholesterol level, which has been implicated as a risk factor for diabetes due to its potential association with insulin insensitivity [48]. Given that individuals with bipolar disorder tend to be physically inactive, they are at greater risk for physical as well as mental health complications. This suggests that exercise may have a dual benefit for individuals with bipolar disorder [15].

Results from open trials of exercise as an adjunctive intervention for bipolar disorder show that it may benefit the physical and mental health of individuals with bipolar disorder. However, to date, no controlled randomized trials have been conducted. For example, these open trials have found that more engagement in exercise was associated with less depressive symptoms, better quality of life, increased functioning as well as less psychiatric comorbidity [22, 49, 50]. Furthermore, dehydroepiandrosterone sulfate (DHEAS), a physiological biomarker, which along with cortisol is implicated in the positive effects of exercise on mood and perceptions of well-being, increased following a bout of 20 minutes of acute exercise in 26 bipolar patients [51].

Only a few studies have investigated the effects of exercise interventions on the symptoms of bipolar disorder. One such study was a retrospective cohort pilot study conducted in an inpatient setting that aimed to identify the utility of an adjunctive walking group for bipolar individuals over the course of 24 months. After exercising, patients who participated in the group had lower levels of depression, anxiety, and stress [26]. An acute bout of exercise (i.e., walking on a treadmill for 20 min at 70% of the individual's maximum heart rate) also significantly improved the mood of bipolar participants [26]. Individuals with bipolar disorder who participated in an exercise program (i.e., eight 30 min walking sessions) had better perceptions of stress reactivity to an acute stressor as well as reduced physiological reactions to stress [52].

In response to the lack of randomized controlled trials examining an exercise-based intervention for bipolar patients, Sylvia and colleagues developed a 20-week cognitive-behavioral intervention for bipolar disorder consisting of three modules: nutrition, exercise, and wellness [28]. Over the course of treatment, participants showed improvements in exercise, nutritional habits, depressive symptoms, and overall functioning [28, 53]. This study provides preliminary data that exercise is acceptable, feasible, and associated with functional improvement of bipolar patients.

Exercise and Comorbid Conditions with Mood Disorders

Studies have also explored the positive effects of exercise on highly comorbid conditions with mood disorders, such as sleep, anxiety, and pain. The high rates of disturbed sleep, anxiety, and pain in mood disorders may indicate that interventions useful in improving these symptoms may also improve the course and functioning of individuals with mood disorders.

Sleep

Sleep disturbance, consisting of insomnia (a subjective perception of inadequate sleep) and sleep deprivation (an objectively measured decrement in sleep), is associated with both manic and depressive episodes [54]. For example, Harvey and colleagues found that 69–99% of patients experienced decreased need for sleep during manic episodes and 23–78% reported hypersomnia when depressed [54]. Rates of insomnia during mood episodes vary greatly with up to 97% of patients experiencing difficulties falling asleep or staying asleep during manic episodes [54]. These data reflect the prevalence of comorbid sleep disturbance amongst individuals with MDD or bipolar disorder. One potential explanation for the high degree of sleep disruption amongst individuals with MDD or bipolar disorder and its social impact is the social zeitgeber theory. This theory states that stress causes disruptions in social, daily routines (e.g., meals, exercise, sleep schedule) which disrupt circadian biological rhythms (e.g., body temperature, hormones). These disruptions may trigger episodes of mania or depression [55]. Studies have found that exercise is a key zeitgeber, or time cue, that helps to entrain other social rhythms [56, 57]. Thus, exercise could help to stabilize one's routines by both entraining rhythms, such as sleep, as well as improving sleep quality [58]. Additionally, previous research has shown that exercise is associated with fewer night time awakenings and less time spent in stage 1 sleep, thus improving sleep quality [59]. Data has also found that sleep disruptions are associated with changes, or reductions, in one's exercise routine [60].

A recent meta-analysis of 66 studies reported small to moderate effects on the positive benefit of both acute and regular exercise on sleep disturbance in non-clinical populations, suggesting that it may be useful to further investigate whether this positive benefit of regular exercise on sleep would also exist in clinical populations (e.g., mood disorders) [61]. Most importantly, effect sizes for improvement in insomnia in this study were comparable between those who engaged in regular exercise and those taking pharmacological and receiving psychological interventions for insomnia. A study on resistance and aerobic exercise training in women with generalized anxiety disorder (often comorbid with primary mood disorders) found that participants reported improved sleep initiation and continuation after six weeks. Furthermore, there was a significant relationship between generalized anxiety disorder clinical severity rating scores and sleep efficiency [62]. Given these preliminary findings on the benefits of exercise for sleep in anxiety disorders and insomnia, exercise may also be beneficial for sleep disturbance in mood disorders given the high rates of comorbid anxiety [4, 63–66]. However, few rigorous studies have investigated the impact of exercise on sleep in psychiatric populations, and, thus, this requires further investigation.

Anxiety

Anxiety is prevalent in both individuals with MDD as well as those with bipolar disorder, with over half of individuals with MDD and 88% of individuals with bipolar disorder having a lifetime comorbid anxiety disorder [2, 4, 63, 65, 66]. In individuals with primary MDD, comorbid anxiety disorders negatively impact treatment outcome and are related to increased impairment, symptom severity, and incidence of suicide [66]. In individuals with primary bipolar disorder, comorbid anxiety disorders are associated with lower quality of life, poorer functioning, and greater likelihood of suicide attempts [63]. Furthermore, panic disorder has

been linked to a higher risk of cardiovascular events, thereby increasing mortality in this clinical population [67]. This increased risk is particularly concerning as only 14% of individuals in the general population report exercising regularly to reduce stress, highlighting the tendency for people to not exercise when anxious and further increasing cardiovascular risk in individuals with anxiety disorders [68].

Given these data, exercise has the potential to dually (i.e., mental and physical health outcomes) benefit individuals who have a mood disorder and comorbid anxiety. There have been several studies that have concluded that exercise is an effective adjunctive treatment for anxiety [21, 24, 69–73]. Specifically, exercise was as effective as psychotherapy in the treatment of anxiety and nearly as effective as pharmacotherapy. Brooks and colleagues found similar results in a randomized controlled study of exercise compared to clomipramine or placebo in 46 outpatients with panic disorder [71]. In particular, exercise was more effective than placebo in alleviating anxiety and depressive symptoms, but was not as effective as clomipramine [71]. Another study found that exercise was an effective adjunctive treatment to group CBT for anxiety with the most pronounced effects in patients diagnosed with social phobia [24]. In summary, there is strong evidence supporting the use of adjunctive exercise interventions for the treatment of comorbid anxiety in individuals with mood disorders.

Pain

Pain (e.g., migraines, chronic pain) is not only associated with functional limitations, poor physical health, higher unemployment, and more frequent doctor visits, but it is also associated with more severe depression [74]. Individuals with primary diagnoses of mood disorders will often also report experiencing some type of secondary pain concerns [74]. Specifically, approximately 65% of depressed patients and 29% of bipolar patients report experiencing pain (e.g., migraine, chronic pain) [74, 75]. In bipolar disorder, perceptions of physical health, including bodily pain, physical functioning, and general health, are associated with worse course of illness [76]. This finding highlights that pain is considered a primary and important component of one's physical health in mood disorders and demonstrates the importance of a treatment that targets mental and physical health outcomes in this clinical population.

Evidence suggests that exercise may accomplish this dual effect by mitigating feelings of pain and reducing depressive symptoms, as well as improving both physical and mental health outcomes. Studies conducted on exercise for fibromyalgia may provide important information about the effects of exercise on pain that can be extended to mood disorders given that fibromyalgia is frequently associated with depression, anxiety, and posttraumatic stress disorder [77, 78]. For example, Ellingson et al. found that a short session of moderate intensity cycling mediated pain modulation in patients with fibromyalgia [31]. Similarly, a 12-week randomized controlled trial in women diagnosed with fibromyalgia found that swimming and walking significantly reduced pain and improved functioning and quality of life [33]. Given the promising data on exercise as a treatment for pain in individuals diagnosed with fibromyalgia, exercise warrants further investigation as an adjunctive treatment for mood disorders that could specifically improve comorbid pain.

Possible Mechanisms of Exercise on Mood Disorders

Several mechanisms have been proposed for the antidepressant effects of exercise, which can be divided in two categories: psychological and biological. Psychological variables include increased autonomy, physical wellbeing, enhanced quality of life, or increased self-esteem and mood [79, 80]. In this review, we opted to review the most promising biological causes of exercise given the burgeoning literature in this area. Specifically, key biological variables include several growth factors (e.g., brain derived neurotrophic factor; BDNF), oxidative stress, and genetics as they have been implicated in the role of exercise-induced neurogenesis and its antidepressant effects [27, 81–90].

Brain Derived Neurotrophic Factor (BDNF)

Data suggests that multiple neuromodulators may explain the antidepressant properties of exercise, yet most of the recent work has focused on the role that BDNF has on exercise for several reasons. First, BDNF supports neurogenesis and the survival and growth of many types of neurons. It is a primary modulator of several neurotransmitters and plays a key role in neuronal survival and synaptic strength [88]. BDNF enhances brain plasticity and could be involved in improving cognition by enhancing learning and memory functions of the hippocampus (i.e., memory consolidation, storage, and long-term memory) [91, 92]. Thus, BDNF resembles the neuroprotection observed from lithium treatment. Lithium decreases gene expression of the protein, GSK3, which increases levels of neuroprotective proteins, such as BDNF. Thus, BDNF may be a crucial mediator in the neurochemical pathway linking lithium with neuroprotection, or increase in grey matter density, in the anterior cingulate gyrus and the hippocampus [93, 94].

Second, BDNF may be an important biomarker as antidepressant medications up-regulate BDNF [95]. BDNF also enhances the effect of antidepressants in animal models, suggesting that antidepressants and BDNF may operate through similar neurochemical pathways [96]. BDNF mimics the effect of antipsychotic drugs on the expression of dopamine receptors in the brain, suggesting that it may reduce manic or elevated mood [97]. MDD patients exhibit lower levels of BDNF than their healthy counterparts, and higher levels of BDNF have been associated with fewer depressive symptoms as well as better cognitive functioning [98–100]. BDNF has also increased following acute and longer programs of exercise; however, some studies report no difference [101–103]. A meta-analysis noted a moderate effect size for increases in BDNF following a single session of exercise and a more pronounced pre- to post-exercise effect following a longer program of regular exercise [104]. Finally, exercise, similar to antidepressants, upregulates BDNF mRNA levels in the hippocampus [105]. BDNF has shown the most robust changes as a result of exercise manipulations [88, 106].

These findings suggest that BDNF may be a viable mechanism by which exercise exerts effects on mood [27]. Subsequent studies should identify the effect of both acute and regular exercise on pre- to post-exercise enhancement of BDNF as well as the effect on resting BDNF levels. Taken together, these data suggest that BDNF may be a primary mechanism of the antidepressant effects of exercise. However, future research is needed as it is likely that BDNF works in conjunction with (and is impacted by) several other signaling pathways.

Oxidative Stress

Evidence suggests that there is mitochondrial dysfunction and abnormal oxidative stress in individuals with MDD or bipolar disorder [83, 85, 86, 107–118]. Mitochondria regulate energy production and generation of ATP through the mitochondrial electron transport chain (ETC). During this process, reactive oxygen species (ROS) are produced, which can lead to oxidative stress and cellular damage, particularly in the absence of antioxidant defenses [117, 119]. Dysfunctional mitochondria can result in neuronal damage via multiple mechanisms: decreased ATP production, oxidative damage of membranes and DNA, abnormal calcium sequestration, and apoptosis [114, 117, 119].

Exercise may impact oxidative stress. This would have clear implications for mood disorders in which there are increases in inflammation and oxidative stress [116, 117, 120]. Specifically, Agarwal et al. found that 16 weeks of moderate-intensity exercise decreased oxidative stress and reduced proinflammatory cytokines in control and hypertensive rat models [121]. However, other studies have found increases in oxidative stress after exercise, particularly in higher intensity exercise [122, 123]. Thus, further research should be conducted to explore the relationship between exercise and oxidative stress in individuals with MDD or bipolar disorder [27, 32, 88, 89, 120, 124].

Epigenetics

Epigenetic changes are modifications to gene expression that do not involve changes in the nucleotide sequence [125]. Even though epigenetic changes do not affect the nucleotide sequence, these changes can persist through multiple cell divisions and across generations [126]. Recent research has indicated that BDNF is upregulated through epigenetic changes. For example, Gomez-Pinilla and colleagues observed increases in rat hippocampal BDNF mRNA and protein through mechanisms of epigenetic regulation after one week of voluntary exercise [87]. Researchers have posited that exercise promotes epigenetic changes, thus promoting homeostasis, including neural plasticity, circadian rhythms, and endocrine and immune regulations [127]. Other investigators have proposed that the epigenetic changes produced through exercise, which they call “eustress” or good stress, can reduce the aging process and have beneficial effects on the musculoskeletal system across the lifespan [128]. Based on recent research, it is possible that exercise is associated with epigenetic changes that are beneficial for individuals with mood disorders [27].

Conclusions

This review suggests that exercise may be an acceptable and feasible alternative or adjunctive intervention to enhance mood, functioning, and comorbid conditions for individuals with MDD or bipolar disorder. The literature suggests that exercise is beneficial as an adjunctive intervention for depression; however, few rigorous studies have been conducted with exercise as an adjunct to treatment as usual, especially for bipolar disorder. For this reason, we included all forms and intensity of exercise in this review, but it is also important to note that not all exercise has the same positive effect. For example, aerobic exercise is typically considered more effective for improving cardiovascular health, increasing well-being, and managing chronic conditions such as diabetes mellitus [34, 129],

while anaerobic exercise has particular benefit for improving respiratory fitness and reducing oxidative stress, and fatigue [32]. Further research is needed to determine the most effective type, duration, and intensity of exercise for individuals with mood disorders, but it is likely that a balance between aerobic and anaerobic exercises would provide the most health benefits. For example, given that mood disorders are characterized by lack of interest and motivation, it may prove beneficial in psychiatric populations to begin an exercise regime that is less extensive than what is currently recommended by the American College of Sports Medicine (5 days a week of at least 30 minutes of moderate to vigorous physical activity) [130].

Future studies should also examine personalized exercise augmentation strategies to both pharmacological and psychological treatments for MDD and bipolar disorder, or strategies based on specific moderators and mediators of outcomes. It is likely that different individuals will benefit greater from (or will be more likely to adhere to) specific types and duration of exercise and thus, developing treatment algorithms based one's demographic and clinical features would maximize treatment efficacy. Further research is also warranted to elucidate the specific mechanisms of action by which exercise improves mood. We highlight a few key pathways (BDNF, oxidative stress, and epigenetics) that have been peripherally demonstrated in clinical trials, but it is likely that multiple interacting pathways are responsible for the antidepressant effects of exercise. With a deeper understanding of these pathways, we can create more effective, and targeted, interventions as well as begin to identify individuals for whom exercise may be the most appropriate or helpful by investigating moderators of exercise.

A key area that necessitates further examination is the role of exercise on mania. Some evidence suggests that mania is associated with increased exercise [27, 53, 131]. This finding remains limited to cross-sectional data, and, to our knowledge, no studies have examined prospectively the impact of increased exercise on mania and vice versa. Future studies should aim to identify order effects as well as optimal exercise levels that improve depressive symptoms but prevent mania.

Overall, there is promising evidence to support the use of exercise in the treatment of mood disorders. With further research determining the ideal frequency, duration, and intensity of exercise and potential mechanisms of action, exercise may become a well-established and efficacious intervention for mood disorders.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *International Journal of Methods in Psychiatric Research*. 2012; 21(3):169–184. [PubMed: 22865617]

2. Merikangas KR, Hagop AS, Angst J, Greenber PE, Hirschfeld RMA, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. *Archives of General Psychiatry*. 2007; 64(5):543–552. [PubMed: 17485606]
3. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. *The American Journal of Psychiatry*. 2005; 162(6):1171–1178. [PubMed: 15930066]
4. Zimmerman M, Chelminski I, McDermt W. Major depressive disorder and axis I diagnostic comorbidity. *The Journal of Clinical Psychiatry*. 2002; 63(3):187–193. [PubMed: 11926716]
5. Hirschfeld RMA. The comorbidity of major depression and anxiety disorders-recognition and management in primary care. *The Primary Care Companion to The Journal of Clinical Psychiatry*. 2001; 3(6):244–254.
6. Forty L, Ulanova A, Jones L, Jones I, Gordon-Smith K, Fraser C, Farmer A, McGuffin P, Lewis CM, Hosang GM, Rivera M, Craddock N. Comorbid medical illness in bipolar disorder. *The British Journal of Psychiatry*. 2014; 205:465–472. [PubMed: 25359927]
7. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, Probst M, De Hert M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. *American Journal of Psychiatry*. 2013; 170(3)
8. Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuvver G, Stoney CM, Wasiak H, McCrindle BW. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: A scientific statement from the American Heart Association. *Circulation*. 2015; 132(10):965–986. [PubMed: 26260736]
9. Teychenne M, Ball K, Salmon J. Sedentary behavior and depression among adults: A review. *International Journal of Behavioural Medicine*. 2010; 17(4):246–254.
10. Vancampfort D, Firth J, Schuch F, Rosenbaum S, De Hert M, Mugisha J, Probst M, Stubbs B. Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis. *Journal of Affective Disorders*. 2016; 201:145–152. [PubMed: 27235817]
11. Fava M. Weight gain and antidepressants. *The Journal of Clinical Psychiatry*. 2000; 61(suppl 11): 1,478–41.
12. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, De Burguera M, De Baptista E, Weiss S, Hernandez L. Lithium and body weight gain. *Pharmacopsychiatry*. 1995; 28(2):35–44. [PubMed: 7624385]
13. Janney CA, Fagiolini A, Swartz HA, Jakicic JM, Holleman RG, Richardson CR. Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. *Journal of Affective Disorders*. 2014; 152–154:498–504.
14. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of Overweight and Obesity in Patients With Bipolar Disorder. *The Journal of Clinical Psychiatry*. 2001; 62(6):486–491. [PubMed: 11465534]
15. Killbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. *Bipolar Disorders*. 2007; 9(5):443–452. [PubMed: 17680914]
16. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. *The Journal of Clinical Psychiatry*. 2009; 70(suppl 3):1,478–29. [PubMed: 19686636]
17. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L. Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *American Journal of Psychiatry*. 2006; 163(2):217–224. [PubMed: 16449474]
18. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatric Clinics of North America*. 1996; 19(2):179–200. [PubMed: 8827185]
19. Stathopoulou G, Powers MB, Berry AC, Smits JAJ, Otto MW. Exercise interventions for mental health: A quantitative and qualitative review. *Clinical Psychology: Science and Practice*. 2006; 13(2):179–193.
20. Schuch FB, Vancampfort D, Rosenbaum S, Richards J, Ward PB, Stubbs B. Exercise improves physical and psychological quality of life in people with depression: A meta-analysis including the evaluation of control group response. *Psychiatry Research*. 2016; 241:47–54. [PubMed: 27155287]

21. Szuhany, KL., Smits, JAJ., Asmundson, GJG., Otto, MW. Exercise for mood and anxiety disorders: A review of efficacy, mechanisms, and barriers. New York: Oxford University Press; 2014.
22. Melo MCA, Daher EDF, Albuquerque SGC, de Bruin VMS. Exercise in bipolar patients: A systematic review. *Journal of Affective Disorders*. 2016; 198:32–38. [PubMed: 26998794]
23. Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, Herman S, Craighead WE, Brosse AL, Waugh R. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosomatic Medicine*. 2007; 69(7):587. [PubMed: 17846259]
24. Merom D, Phongsavan P, Wagner R, Chey T, Marnane C, Steel Z, Silove D, Bauman A. Promoting walking as an adjunct intervention to group cognitive behavioral therapy for anxiety disorders: A pilot group randomized trial. *Journal of Anxiety Disorders*. 2008; 22(6):959–968. [PubMed: 17988832]
25. Kruisdijk FR, Hendriksen IJM, Tak ECPM, Beekman ATF, Hopman-Rock M. Effect of running therapy on depression (EFFORT-D). Design of a randomised controlled trial in adult patients [ISRCTN 1894]. *BMC Public Health*. 2012; 12(1):1–9. [PubMed: 22214479]
- 26. Ng F, Dodd S, Berk M. The effects of physical activity in the acute treatment of bipolar disorder: A pilot study. *Journal of Affective Disorders*. 2007; 101(1):259–262. An important study that showed changes in mood, anxiety, and stress after an exercise intervention. [PubMed: 17182104]
27. Thomson D, Alyna T, Lauder S, Gigler ME, Berk L, Singh AB, Pasco JA, Berk M, Sylvia LG. A brief review of exercise, bipolar disorder, and mechanistic pathways. *Frontiers in Psychology*. 2015; 6(147)
- 28. Sylvia LG, Salcedo S, Bernstein EE, Baek JH, Nierenberg AA, Deckersbach T. Nutrition, exercise, and wellness treatment in bipolar disorder: Feasibility, acceptability and preliminary efficacy. *International Journal of Bipolar Disorder*. 2013; 1(1) One of very few studies using a novel exercise intervention in bipolar individuals.
29. El-Rafie MM, Khafagy GM, Gamal MG. Effect of aerobic exercise during pregnancy on antenatal depression. *International Journal of Women's Health*. 2016; 8:53.
30. Siqueira CC, Valiengo LL, Carvalho AF, Santos-Silva PR, Missio G, de Sousa RT, Di Natale G, Gattaz WF, Moreno RA, Machado-Vieira R. Antidepressant efficacy of adjunctive aerobic activity and associated biomarkers in major depression: A 4-week, randomized, single-blind, controlled clinical trial. *PLoS ONE*. 2016; 11(5):e0154195. [PubMed: 27152523]
31. Ellingson LD, Stegner AJ, Schwabacher IJ, Koltyn KF, Cook DB. Exercise Strengthens Central Nervous System Modulation of Pain in Fibromyalgia. *Brain Sciences*. 2016; 6(1):8.
32. Bloomer RJ, Goldfarb AH. Anaerobic exercise and oxidative stress: A review. *Canadian Journal of Applied Physiology*. 2004; 29(3):245–263. [PubMed: 15199226]
33. Fernandes G, Jennings F, Cabral MVN, Buosi ALP, Natour J. Swimming improves pain and functional capacity of patients with fibromyalgia: A randomized controlled trial. *Archives of Physical Medicine and Rehabilitation*. 2016 in press.
34. Norris R, Carroll D, Cochrane R. The effects of aerobic and anaerobic training on fitness, blood pressure, and psychological stress and well-being. *Journal of Psychosomatic Research*. 1990; 34(4):367–375. [PubMed: 2376838]
35. Mathers, C., Fat, DM., Boerma, JT. The Global Burden of Disease: 2004 Update. World Health Organization; 2008.
36. Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). *Journal of Affective Disorders*. 2013; 151(1):59–65. [PubMed: 23790554]
- 37. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: Efficacy and dose response. *American Journal of Preventive Medicine*. 2005; 28(1):1–8. One of very few randomized clinical trial investigating the optimal dose of exercise.
38. Daley A. Exercise and depression: A review of reviews. *Journal of Clinical Psychology in Medical Settings*. 2008; 15(2):140–147. [PubMed: 19104978]
39. Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: Systematic review and meta-regression analysis of randomised controlled trials. *British Medical Journal*. 2001; 322(7289):763. [PubMed: 11282860]

40. Mota-Pereira J, Carvalho S, Silverio J, Fonte D, Pizarro A, Teixeira J, Ribeiro JC, Ramos J. Moderate physical exercise and quality of life in patients with treatment-resistant major depressive disorder. *Journal of Psychiatric Research*. 2011; 45(12):1657–1659. [PubMed: 21908006]
41. Herring MP, Puetz TW, O'Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness: A systematic review and meta-analysis of randomized controlled trials. *Archives of Internal Medicine*. 2012; 172(2):101–111. [PubMed: 22271118]
42. Gill, A., Womack, R., Safranek, S. Does exercise alleviate symptoms of depression? *Clinical Inquiries*, 2010 (MU). 2010.
43. Carek PJ, Laibstain SE, Carek SM. Exercise for the treatment of depression and anxiety. *The International Journal of Psychiatry in Medicine*. 2011; 41(1):15–28. [PubMed: 21495519]
44. Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. *Journal of Psychiatric Practice*. 2013; 19(3):204–212. [PubMed: 23653077]
45. Seime RJ, Vickers KS. The challenges of treating depression with exercise: From evidence to practice. *Clinical Psychology: Science and Practice*. 2006; 13(2):194–197.
46. Vancampfort D, Sienaert P, Wyckaert S, De Hert M, Stubbs B, Soundy A, De Smet J, Probst M. Health-related physical fitness in patients with bipolar disorder vs. healthy controls: An exploratory study. *Journal of Affective Disorders*. 2015; 177:22–27. [PubMed: 25745831]
47. Proudfoot J, Whitton A, Parker G, Doran J, Manicavasagar V, Delmas K. Triggers of mania and depression in young adults with bipolar disorder. *Journal of Affective Disorders*. 2012; 143(1): 196–202. [PubMed: 22884233]
48. Amati F, Dubé JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. *Diabetes Care*. 2009 in press.
49. Wright KA, Everson-Hock ES, Taylor AH. The effects of physical activity on physical and mental health among individuals with bipolar disorder: A systematic review. *Mental Health and Physical Activity*. 2009; 2(2):86–94.
50. Ströhle A, Höfler M, Pfister H, Muller A, Hoyer J, Wittchen H, Lieb R. Physical activity and prevalence and incidence of mental disorders in adolescents and young adults. *Psychological Medicine*. 2007; 37(11):1657–1666. [PubMed: 17579930]
51. Hays, AE. Effect of an acute bout of aerobic exercise on dehydroepiandrosterone sulphate (DHEAS) in clinically diagnosed bipolar subjects. University of Pittsburgh; 2007.
52. Edenfield TM. Exercise and mood: Exploring the role of exercise in regulating stress reactivity in bipolar disorder. *Dissertation Abstracts International: Section B: The Sciences and Engineering*. 2008; 68(8-B):5566.
53. Sylvia LG, Salcedo S, Berinstein EE, Baek JH, Nierenberg AA, Deckersbach T. Nutrition, exercise, and wellness treatment in bipolar disorder: Proof of concept for a consolidated intervention. *International Journal of Bipolar Disorders*. 2013; 1(1):1–7. [PubMed: 25505668]
54. Harvey AG. Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. *American Journal of Psychiatry*. 2008; 165(7):820–829. [PubMed: 18519522]
55. Grandin LD, Alloy LB, Abramson LY. The social zeitgeber theory, circadian rhythms, and mood disorders: Review and evaluation. *Clinical Psychology Review*. 2006; 26(6):679–694. [PubMed: 16904251]
56. Edgar DM, Dement WC. Regularly scheduled voluntary exercise synchronizes the mouse circadian clock. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 1991; 261(4):R928–R933.
57. Escames G, Ozturk G, Bano Otalora B, Pozo MJ, Madrid JA, Reiter RJ, Serrano E, Concepcion M, Acuna Castroviejo D. Exercise and melatonin in humans: Reciprocal benefits. *Journal of Pineal Research*. 2012; 52(1):1–11. [PubMed: 21848991]
58. Solberg LC, Horton TH, Turek FW. Circadian rhythms and depression: Effects of exercise in an animal model. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 1999; 276(1):R152–R161.
59. King AC, Pruitt LA, Woo S, Castro CM, Ahn DK, Vitiello MV, Woodward SH, Bliwise DL. Effects of moderate-intensity exercise on polysomnographic and subjective sleep quality in older

- adults with mild to moderate sleep complaints. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 2008; 63(9):997–1004.
60. McGlinchey EL, Gershon A, Eidelman P, Kaplan KA, Harvey AG. Physical activity and sleep: Day-to-day associations among individuals with and without bipolar disorder. *Mental Health and Physical Activity*. 2014; 7(3):183–190. [PubMed: 25506392]
 61. Kredlow MA, Capozzoli MC, Hearon BA, Calkins AW, Otto MW. The effects of physical activity on sleep: A meta-analytic review. *Journal of Behavioral Medicine*. 2015; 38(1):427–449. [PubMed: 25596964]
 62. Herring MP, Kline CE, O'Connor PJ. Effects of exercise on sleep among young women with Generalized Anxiety Disorder. *Mental Health and Physical Activity*. 2015; 9:59–66. [PubMed: 26566400]
 63. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH. Anxiety disorder comorbidity in bipolar disorder patients: Data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *American Journal of Psychiatry*. 2004; 161(12):2222–2229. [PubMed: 15569893]
 64. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF. Anxiety disorders in major depression. *Comprehensive Psychiatry*. 2000; 41(2):97–102. [PubMed: 10741886]
 65. McElroy SL, Altshuler LL, Suppes T, Keck PE, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, Rush AJ, Post RM. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. *American Journal of Psychiatry*. 2001; 158(3):420–426. [PubMed: 11229983]
 66. Bakish D. The patient with comorbid depression and anxiety: The unmet need. *The Journal of Clinical Psychiatry*. 1999; 60(6):20–24.
 67. Coryell W, Noyes R, House JD. Mortality among outpatients with anxiety disorders. *American Journal of Psychiatry*. 1986; 143(4):508–510. [PubMed: 3953892]
 68. Physical Activity Reduces Stress. Jun 24. 2016 Available from: <http://www.adaa.org/understanding-anxiety/related-illnesses/other-related-conditions/stress/physical-activity-reduces-stress>
 69. Asmundson GJG, Fetzner MG, DeBoer LB, Powers MB, Otto MW, Smits JAJ. Let's get physical: A contemporary review of the anxiolytic effects of exercise for anxiety and its disorders. *Depression and Anxiety*. 2013; 30(4):362–373. [PubMed: 23300122]
 70. DeBoer LB, Powers MB, Utschig AC, Otto MW, Smits JAJ. Exploring exercise as an avenue for the treatment of anxiety disorders. *Expert Review of Neurotherapeutics*. 2012; 12(8):1011–1022. [PubMed: 23002943]
 71. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Rütther E. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. *American Journal of Psychiatry*. 1998
 72. Szuhany, KL., Smits, JAJ., Asmundson, GJG., Otto, MW. Exercise for Mood and Anxiety Disorders: A Review of Efficacy, Mechanisms, and Barriers. In progress
 73. Wipfli BM, Rethorst CD, Landers DM. The anxiolytic effects of exercise: A meta-analysis of randomized trials and dose-response analysis. *Journal of Sport & Exercise Psychology*. 2008; 30(4):392. [PubMed: 18723899]
 74. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. *Archives of Internal Medicine*. 2003; 163(20):2433–2445. [PubMed: 14609780]
 75. Stubbs B, Eggermont L, Mitchell AJ, De Hert M, Correll CU, Soundy A, Rosenbaum S, Vancampfort D. The prevalence of pain in bipolar disorder: A systematic review and large-scale meta-analysis. *Acta Psychiatrica Scandinavica*. 2015; 131(2):75–88. [PubMed: 25098864]
 76. Bernstein EE, Rabideau DJ, Gigler ME, Nierenberg AA, Deckersbach T, Sylvia LG. Patient perceptions of physical health and bipolar symptoms: The intersection of mental and physical health. *Journal of Affective Disorders*. 2016; 189:203–206. [PubMed: 26451504]
 77. Thieme K, Turk DC, Flor H. Comorbid Depression and Anxiety in Fibromyalgia Syndrome: Relationship to Somatic and Psychosocial Variables. *Psychosomatic Medicine*. 2004; 66(6):837–844. [PubMed: 15564347]

78. Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: Overlapping syndromes or post-traumatic fibromyalgia syndrome? *Seminars in Arthritis and Rheumatism*. 2002; 32(1):38–50. [PubMed: 12219319]
79. Carta MG, Hardoy MC, Pilu A, Sorba M, Floris AL, Mannu FA, Baum A, Cappai A, Velluti C, Salvi M. Improving physical quality of life with group physical activity in the adjunctive treatment of major depressive disorder. *Clinical Practice and Epidemiology in Mental Health*. 2008; 4(1):1–6. [PubMed: 18221549]
80. Annesi JJ, Unruh JL. Relations of exercise, self-appraisal, mood changes and weight loss in obese women: testing propositions based on Baker and Brownell's (2000) model. *The American Journal of the Medical Sciences*. 2008; 335(3):198–204. [PubMed: 18344693]
81. Duman RS. Neurotrophic factors and regulation of mood: Role of Exercise, diet and metabolism. *Neurobiology of Aging*. 2005; 26(Suppl 1):S88–S93.
82. Ernst C, Olson AK, Pinel JP, Lam RW, Christie BR. Antidepressant effects of exercise: Evidence for an adult-neurogenesis hypothesis? *Journal of Psychiatry Neuroscience*. 2006; 31(2):84–91. [PubMed: 16575423]
83. Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ, Froimowitz MP, Hassinger LC, Menesale EB, Sargent LW, Logan DJ, Carpenter AE, Cohen BM. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. *The American Journal of Pathology*. 2010; 177(2):575–85. [PubMed: 20566748]
84. Dinas PC, Koutedakis Y, Flouris AD. Effects of exercise and physical activity on depression. *Irish Journal of Medical Science*. 2011; 180(2):319–325. [PubMed: 21076975]
85. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. *Molecular Psychiatry*. 2006; 11(3):241–251. [PubMed: 16288314]
86. Clay HB, Sullivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. *International Journal of Developmental Neuroscience*. 2011; 29(3):311–24. [PubMed: 20833242]
87. Gomez-Pinilla F, Zhuang Y, Feng J, Ying Z, Fan G. Exercise impacts brain-derived neurotrophic factor plasticity by engaging mechanisms of epigenetic regulation. *European Journal of Neuroscience*. 2011; 33(3):383–390. [PubMed: 21198979]
88. Cotman CW, Berchtold NC, Christie L. Exercise builds brain health: Key roles of growth factor cascades and inflammation. *Trends in Neuroscience*. 2007; 30(9):464–472.
89. Schuch FB, Vasconcelos-Moreno MP, Borowsky C, Zimmermann AB, Wollenhaupt-Aguiar B, Ferrari P, Fleck MPA. The effects of exercise on oxidative stress (TBARS) and BDNF in severely depressed inpatients. *European Archives of Psychiatry and Clinical Neuroscience*. 2014; 264(7):605–613. [PubMed: 24487616]
90. Marais L, Stein DJ, Daniels WMU. Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. *Metabolic Brain Disease*. 2009; 24(4):587–597. [PubMed: 19844781]
91. Schinder AF, Poo M. The neurotrophin hypothesis for synaptic plasticity. *Trends in Neuroscience*. 2000; 23(12):639–645.
92. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. *Growth Factors*. 2004; 22(3):123–131. [PubMed: 15518235]
93. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC. Greater cortical grey matter density in lithium-treated patients with bipolar disorder. *Biological Psychiatry*. 2007; 62(1):7–16. [PubMed: 17240360]
94. Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti M, Dierschke N, Hayashi KM, Klunder AD, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Soares JC. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. *Neuropsychopharmacology*. 2008; 33(6):1229–38. [PubMed: 17687266]
95. Duman CH, Schlesinger L, Russell DS, Duman RS. Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. *Brain Research*. 2008; 1199:148–158. [PubMed: 18267317]

96. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP. Physical activity-antidepressant treatment combination: Impact on brain-derived neurotrophic factor and behavior in an animal model. *Behavior Brain Research*. 2001; 120(1):87–95.
97. Guillin O, Demily C, Thibaut F. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. *International Review of Neurobiology*. 2007; 78:377–395. [PubMed: 17349867]
98. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. *International Journal of Neuropsychopharmacology*. 2008; 11(8):1169–1180. [PubMed: 18752720]
99. Lee B, Kim H, Park S, Kim Y. Decreased plasma BDNF level in depressive patients. *Journal of Affective Disorders*. 2007; 101(1):239–244. [PubMed: 17173978]
100. Cirulli F, Berry A, Chiarotti F, Alleva E. Intrahippocampal administration of BDNF in adult rats affects short-term behavioral plasticity in the Morris water maze and performance in the elevated plus-maze. *Hippocampus*. 2004; 14(7):802–807. [PubMed: 15382250]
101. Gustafsson G, Lira CM, Johansson J, Wisén A, Wohlfart B, Ekman R, Westrin A. The acute response of plasma brain-derived neurotrophic factor as a result of exercise in major depressive disorder. *Psychiatry Research*. 2009; 169(3):244–248. [PubMed: 19729204]
102. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM. Exercise training increases size of hippocampus and improves memory. *Proceedings of the National Academy of Sciences*. 2011; 108(7):3017–3022.
103. Tups MSP, Greer TL, Kurian BT, Grannemann BD, Carmody TJ, Huebinger R, Rethorst C, Trivedi MH. Effects of serum brain derived neurotrophic factor on exercise augmentation treatment of depression. *Journal of Psychiatric Research*. 2011; 45(10):1301–1306. [PubMed: 21641002]
104. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. *Journal of Psychiatric Research*. 2015; 60:56–64. [PubMed: 25455510]
105. Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. *Neuroscience*. 2000; 101(2):305–312. [PubMed: 11074154]
106. Ma Q. Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. *Neuroscience Bulletin*. 2008; 24(4):265–267. [PubMed: 18668156]
107. Andrezza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. *Journal of Neurochemistry*. 2013; 127(4):552–561. [PubMed: 23692477]
108. Berk M, Kapczynski F, Andrezza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. *Neuroscience and Biobehavioral Reviews*. 2011; 35(3):804–817. [PubMed: 20934453]
109. Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. Role of oxidative stress in pathophysiology of bipolar disorder. *Neurochemical Research*. 2010; 35(3):1295–1301. [PubMed: 20499165]
110. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. *Archives of General Psychiatry*. 2004; 61(3):301–308.
111. Munakata K, Tanaka M, Mori K, Washizuka S, Yoneda M, Tajima O, Akiyama T, Nanko S, Kunugi H, Tadokoro K, Ozaki N, Inada T, Sakamoto K, Fukunaga T, Iijima Y, Iwata N, Tatsumi M, Yamada K, Yoshikawa T, Kato T. Mitochondrial DNA 3644T→C mutation associated with bipolar disorder. *Genomics*. 2004; 84(6):1041–1050. [PubMed: 15533721]
112. Naydenov AV, MacDonald ML, Ongur D, Konradi C. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. *Archives of General Psychiatry*. 2007; 64(5):555–564. [PubMed: 17485607]

113. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. *Molecular Psychiatry*. 2005; 10(10):900–919. [PubMed: 16027739]
114. Wang J-F. Defects of mitochondrial electron transport chain in bipolar disorder: Implications for mood-stabilizing treatment. *Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie*. 2007; 52(12):753–762. [PubMed: 18186175]
115. Erkan OM, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. *International Journal of Clinical Psychopharmacology*. 2004; 19(2): 89–95.
116. Michel TM, Pülschen D, Thome J. The role of oxidative stress in depressive disorders. *Current Pharmaceutical Design*. 2012; 22(46):5890–5899.
117. Tobe EH. Mitochondrial dysfunction, oxidative stress, and major depressive disorder. *Neuropsychiatric Disease and Treatment*. 2013; 9:567–573. [PubMed: 23650447]
118. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: Evidence base and therapeutic interventions. *International Journal of Neuropsychopharmacology*. 2008; 11(6):851–876. [PubMed: 18205981]
119. Ng F, Berk M, Dean O, Busch AI. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. *International Journal Neuropsychopharmacology*. 2008; 22(6):851–876.
120. Handschin C, Spiegelman BM. The role of exercise and PGC1 α in inflammation and chronic disease. *Nature*. 2008; 454(7203):463–469. [PubMed: 18650917]
121. Agarwal D, Haque M, Sriramula S, Mariappan N, Pariat R, Francis J. Role of proinflammatory cytokines and redox homeostasis in exercise-induced delayed progression of hypertension in spontaneously hypertensive rats. *Hypertension*. 2009; 54(6):1393–1400. [PubMed: 19841289]
122. Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. *Toxicology*. 2003; 189(1):41–54. [PubMed: 12821281]
123. Gleeson M. Immune function in sport and exercise. *Journal of Applied Physiology*. 2007; 103(2): 693–699. [PubMed: 17303714]
124. Alsuwaidan MT, Kucyi A, Law CWY, McIntyre RS. Exercise and bipolar disorder: A review of neurobiological mediators. *NeuroMolecular Medicine*. 2009; 11(4):328–336. [PubMed: 19649751]
125. Moore, DS. *The Developing Genome: An Introduction to Behavioral Epigenetics*. Oxford University Press; 2015.
126. Bird A. Perceptions of epigenetics. *Nature*. 2007; 447(7143):396–398. [PubMed: 17522671]
127. Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: Neuroplasticity and epigenetic changes in a transgenic mouse model of depression. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2012; 367(1601):2485–2494.
128. Sanchis-Gomar F, Garcia-Gimenez JL, Perez-Quilis C, Gomez-Cabrera MC, Pallardo FV, Lippi G. Physical exercise as an epigenetic modulator: Eustress, the “positive stress” as an effector of gene expression. *The Journal of Strength & Conditioning Research*. 2012; 26(12):3469–3472. [PubMed: 22561977]
129. Mersy DJ. Health benefits of aerobic exercise. *Postgraduate Medicine*. 1991; 90(1):103–112.
130. Garber CE, Blissmer B, Deschenes MR, Franklin B, Lamonte MJ, Lee I, Nieman DC, Swain DP. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. *Medicine & Science in Sports & Exercise*. 2011; 43(7):1334–1359. [PubMed: 21694556]
131. Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Bobo WV. Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. *Journal of Affective Disorders*. 2013; 151(2): 722–727. [PubMed: 23993440]